Drug Combination Details
| General Information of the Combination (ID: C33351) | |||||
|---|---|---|---|---|---|
| Name | Spiramycin NP Info | + | Nitazoxanide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Toxoplasmosis
[ICD-11: 1F57]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vivo Model | 6-8 weeks old Swiss strain albino mice were used in this study. | |||||
| Experimental
Result(s) |
SP-metronidazole gave the foremost effect on both mice survival rate and parasite load in the liver, spleen and brain. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Effect of nitazoxanide and spiramycin metronidazole combination in acute experimental toxoplasmosis. Heliyon. 2020 Apr 16;6(4):e03661. | |||
